chrisvoncsefalvay/vaers-outcomes huggingface dataset:
arm was swollen; hard; warm to touch; itching; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE SWELLING (arm was swollen), VACCINATION SITE INDURATION (hard), VACCINATION SITE WARMTH (warm to touch) and VACCINATION SITE PRURITUS (itching) in an 87-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029L20A and 023M20A) for COVID-19 vaccination.     No medical history was provided by reporter.  Concomitant products included METFORMIN, VITAMINS NOS (MULTIVITAMINUM) and LISINOPRIL for an unknown indication.   On 23-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 20-Feb-2021, the patient experienced VACCINATION SITE SWELLING (arm was swollen), VACCINATION SITE INDURATION (hard), VACCINATION SITE WARMTH (warm to touch) and VACCINATION SITE PRURITUS (itching). On 25-Feb-2021, VACCINATION SITE SWELLING (arm was swollen), VACCINATION SITE INDURATION (hard) and VACCINATION SITE WARMTH (warm to touch) had resolved. At the time of the report, VACCINATION SITE PRURITUS (itching) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment medications were not provided by reporter.
Erythema, edema, warmth at injection site R deltoid. Treated with Keflex.
Little bit appetite have been different; Difficult for patient to take the drug; to swallow it whole; It came back positive still; rapid test came positive; This spontaneous case was reported by a consumer and describes the occurrence of APPETITE DISORDER (Little bit appetite have been different), DYSPHAGIA (Difficult for patient to take the drug; to swallow it whole) and COVID-19 (It came back positive still; rapid test came positive) in a  patient of an unknown age and gender who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for an unknown indication.    No Medical History information was reported.   On 06-Sep-2023, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) at an unspecified dose. On an unknown date, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (unknown route) 1 dosage form. On an unknown date, the patient experienced APPETITE DISORDER (Little bit appetite have been different), DYSPHAGIA (Difficult for patient to take the drug; to swallow it whole) and COVID-19 (It came back positive still; rapid test came positive). At the time of the report, APPETITE DISORDER (Little bit appetite have been different), DYSPHAGIA (Difficult for patient to take the drug; to swallow it whole) and COVID-19 (It came back positive still; rapid test came positive) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: Positive.         No concomitant medication was reported.  Reportedly, patient had 4 rounds of all, whatever shot was out there booster's, bivalent (Further suspect product was not appropriately clarified, hence captured as Unspecified Booster Shot) the whole thing but round was Moderna.  No treatment information was provided.
Systemic: Allergic: Anaphylaxis-Severe, Systemic: Allergic: Difficulty Breathing-Severe, Systemic: Hypotension-Medium, Systemic: Seizure-Severe, Additional Details: Approx. 15 minutes after getting his COVID vaccine pt. notifed clinic staff that he was feeling unwell and his heartbeat was irregular. Pt. then started to collapse and after being assisted to the ground had a seizure lasting approx. 10 seconds. After waking back up from seizure pt. had trouble breathing. Clinic staff notified me and I immediately administered 0.3 mg of epinephrine via an auto-injector. 911 was called and Pt. was able to sit back up while he waited for EMS.
1-2 days after receiving hep b vaccine. right side facial pain radiating to neck constant to intermittent, pain described as excruciating and shocking pain like needles in face/neck
This case was reported by a consumer (subject) and described the occurrence of not responding to therapy in a 65-year-old male subject who was vaccinated with ENGERIX B (GlaxoSmithKline). A physician or other health care professional has not verified this report. Concurrent medical conditions included hepatitis C and liver cirrhosis. On an unspecified dates the subject received 1st dose, 2nd dose and 3rd dose of ENGERIX B (unknown details) and experienced not responding to therapy. The subject stated that he "has received the GSK hepatitis vaccine 7 times and it never worked. Half the time he develops antibodies, but 2 months later they are gone." The subject did not provide additional details.
Got flu shot L thigh a week ago, then developed 3-4 red, blanching 8-10 mm sl. raised lesions, which may be tender.
Small quarter size rash appeared under right eye, red, raised and bumpy. Not painful or itchy. Pt said it was already improved slightly on 11/5. Swollen lymph node on left side, not painful also appeared on 11/4. Pt had not yet treated with anything besides BENADRYL.
48 Hours after shot, hives and rash broke out on legs from mid thigh down. Itchy, raises bumps prevalent behind knees calves and ankles
1st dose on 3/16/21 and was told not to take 2nd dose; Had pneumonia; This spontaneous case was reported by an other health care professional and describes the occurrence of PNEUMONIA (Had pneumonia) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included PREDNISOLONE for an unknown indication.    On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced PNEUMONIA (Had pneumonia) (seriousness criterion medically significant). On an unknown date, the patient experienced INTENTIONAL DOSE OMISSION (1st dose on 3/16/21 and was told not to take 2nd dose). At the time of the report, PNEUMONIA (Had pneumonia) outcome was unknown and INTENTIONAL DOSE OMISSION (1st dose on 3/16/21 and was told not to take 2nd dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment medications were reported.   The patient had pneumonia and didn't know it ended up keeping the pneumonia for months and was told not to get the 2nd dose. patient was now finishing up a 90 prescription of antibiotics and Patient was on Prednisolone drops for one eye and wanted to know if could take 2 dose or need to start over. Company comment: This is a spontaneous case concerning unknown age and gender patient with no medical history reported, who experienced the serious unexpected , according Agency,  event of pneumonia. The event occurred after the first dose of mRNA-1273 vaccine. The rechallenge was not applicable. The case was assessed as serious due to Important medical event, patient reported keeping the pneumonia for months and a 90 prescription of antibiotics per treatment. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   Reporter did not allow further contact; Sender's Comments: This is a spontaneous case concerning unknown age and gender patient with no medical history reported, who experienced the serious unexpected , according Agency,  event of pneumonia. The event occurred after the first dose of mRNA-1273 vaccine. The rechallenge was not applicable. The case was assessed as serious due to Important medical event, patient reported keeping the pneumonia for months and a 90 prescription of antibiotics per treatment. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
2 days post vaccination patient broke out in a rash on torso and arm/legs, resembling and dx as pityriasis rosea
approx. 1 hour following inject experienced severe head ache with blurred vision; approx. 10 days following injection large swelling, redness, and warmth at injection site, appears like muscle swelling to size/shape of an egg
Bad technique used to administer the vaccine/ it was "not really as bad as the first"; This spontaneous case was reported by a consumer and describes the occurrence of WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (Bad technique used to administer the vaccine/ it was "not really as bad as the first") in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In November 2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In November 2021, the patient experienced WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (Bad technique used to administer the vaccine/ it was "not really as bad as the first"). At the time of the report, WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (Bad technique used to administer the vaccine/ it was "not really as bad as the first") outcome was unknown.            No concomitant medications were provided. Patient complained about the bad technique used to administer the vaccine to her for also her first booster and it was not really as bad as the first. Patient mentioned that she received the first booster dose on Nov last year. No treatment medications were reported.   This case was linked to MOD-2021-226740, MOD-2021-025166 (Patient Link).
headache; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (headache) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 028A21A and 025A21A) for COVID-19 vaccination.     Concurrent medical conditions included Breast cancer (Patient's left breast removed because of breast cancer). Concomitant products included ANASTROZOLE, ATORVASTATIN, CARBIDOPA, LEVODOPA and LISINOPRIL for an unknown indication.   On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 30-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced HEADACHE (headache). On 30-Mar-2021, HEADACHE (headache) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Action taken with mRNA-1273 in response to the event was not applicable.
Per patient she developed a lump on her left shoulder that went away after 3 days.  NP consulted and stated patient experienced Lymphedema and VAERS to be submitted.
couldn't smell or taste anything; coughing; headaches; fatigued; fever; This spontaneous case was reported by a consumer and describes the occurrence of SENSORY LOSS (couldn't smell or taste anything), COUGH (coughing), HEADACHE (headaches), FATIGUE (fatigued) and PYREXIA (fever) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced SENSORY LOSS (couldn't smell or taste anything), COUGH (coughing), HEADACHE (headaches), FATIGUE (fatigued) and PYREXIA (fever). The patient was treated with DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE, EPHEDRINE SULFATE, ETHANOL, PARACETAMOL (NYQUIL) at an unspecified dose and frequency; DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, PARACETAMOL, PSEUDOEPHEDRINE HYDROCHLORIDE (DAYQUIL) at an unspecified dose and frequency and PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, SENSORY LOSS (couldn't smell or taste anything), COUGH (coughing), HEADACHE (headaches), FATIGUE (fatigued) and PYREXIA (fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications provided.
Approx 8 hours after vaccination (around 8:00 pm), patient complained of feeling tired and achy, and felt as though he had a fever although he did not.    Approx 9 hours after vaccination (around 9:00 pm), he had 100.2* F fever, and took 1000 mg of acetaminophen.   Approx 3 hours later (12:30 pm), his fever was 102* F, and he took another 1000 mg of acetaminophen.   Approx 2 hours later (after 2:00 am), his fever apparently broke as he was sweating.   Approx 3 hours after that (5:30 am), his temperature was 98.4* and he was more comfortable.  24 hours after vaccination, he is afebrile but still complains of malaise.
Significant Left arm muscle pain started 24 hours after injection, continued for 3-4 weeks slowly improving. Previous flu vaccines without difficulty.
Initial unsolicited report received from a non- healthcare professional on 20 November 2015. This case involves a 71-year-old female patient who was vaccinated with a dose of Fluzone (batch number and manufacturer was unknown, expiry date, dose, dose in series, route and site of administration were not reported) on 13 November 2015. Illness at time of vaccination and any other vaccinations within 4 weeks of vaccinations reported as didn't ask. Pre-existing physician diagnosed allergies, birth defects, medical conditions reported as unknown. Concomitant medications were not reported. On 13 November 2015, few second following the vaccination, the patient had developed jaw swelling, may have had rash. The patient's laboratory data and corrective treatment was not reported. The outcome of event was unknown. List of documents held by sender: none. Follow up information received from non-healthcare professional on 09 February 2015. Patient received 0.5ml intramuscular dose of Fluzone (batch number U1487AA, manufacturer: SANOFI PASTEUR INC.) in left deltoid at 13:50.
This spontaneous report as received from a Registered Nurse (RN) refers to 5 patients who were vaccinated with doses of PNEUMOVAX23 (dose, frequency and route unknown). Nurse was reporting that the patients reported to had reactions after receiving PNEUMOVAX23. All the patients experienced fever and chills along with swelling and tenderness at the injection site. One patient experienced blisters (which was captured in Marss# 1212USA005320). Three patients required antibiotic treatments. This case refers to one of the patients who on 19-NOV-2012 the patient was vaccinated with a dose of PNEUMOVAX23 (lot#H010515, expired date 14-FEB-2013). At the time of reporting the patient had recovered from the adverse events. This is one of several reports received from the same source. Additional information has been requested.
severe pain under his ribs on both sides,more towards the stomach; impaired fasting blood glucose; This is a spontaneous report from a contactable consumer. This 84-Year-old male consumer (patient).  An 84-year-old (non-pregnant) female patient received a dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot Number: unknown, Expiration date: unknown), via unspecified route, administered on 09Feb2021 (at the age of 83-year-old) as dose 2, single for COVID-19 immunization. Patient received a dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot Number: unknown, Expiration date: unknown), via unspecified route, administered on an unspecified date (at the age of 83-year-old) as dose 1, single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. On 09Feb2021, after the vaccination, the patient waited for 15 minutes and then had a 1520-minute car ride home and during that drive he had severe pain under his ribs on both sides, more towards the stomach. When he does his blood work up checking his calcium and such, instead of giving him a number on glucose it doesn't give a number, it reads impaired fasting blood glucose. Caller is wondering if that sever hurt that he had damage something that is causing his blood work to say impaired fasting blood glucose. He gets his blood work done every three months unless something is going on. He takes a couple of different medications and the vaccine has caused him some expense. The patient lab data includes blood calcium on an unspecified date with unknown result and blood glucose levels on an unspecified date with a result of impaired fasting blood glucose. The outcome of the event Fasting blood glucose abnormal was unknown and pain was recovered on an unspecified date.  No follow-up attempts possible. No further information expected.
About 2 weeks after 2nd vaccine dose: tingling and numbness, chills on left side of body and left leg/foot, body and muscle twitching, heart palpitations, chest pain, face tingling and twitching, nerve and joint pain and weakness in legs, stiffness in legs and difficulty walking, nerve pain in body, increased and intensified headache on left side of head.
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 13-OCT-2013 the patient was vaccinated with an improperly stored dose of GARDASIL (lot # J002641, expiration date: 04-NOV-2016; dose, frequency and route unspecified). No adverse effects were reported. The storage criteria was refrigerator (R). Celsius conversion of the lowest recorded temperature was 1 (Fahrenheit degree/Celsius). The total cumulative excursion time was 48 hours with the lowest recorded temperature 1 (Fahrenheit degree/Celsius) and the type of excursion (R/F) was R. This is one of several reports received from the same source. Additional information has been requested.
total time out of range is 2 days with a minimum of 9.2C and maximum of 28.3C; 30 minutes with a minimum of 12.3C and maximum of 15.6C; 1 hour with a minimum of negative 1.8C and maximum of 1.8C reported with no adverse event; Initial information received on 29-Apr-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 71 years old and unknown gender patient who experienced total time out of range is 2 days with a minimum of 9.2c and maximum of 28.3c; 30 minutes with a minimum of 12.3c and maximum of 15.6c; 1 hour with a minimum of negative 1.8c and maximum of 1.8c reported with no adverse event while receiving vaccine influenza quadrival A-B high dose hv vaccine [Fluzone high-dose quadrivalent].   The patient's past medical history, medical treatment(s), concomitant medication, vaccination(s) and family history were not provided.    On an unknown date, the patient received suspect influenza quadrival A-B high dose hv vaccine (lot UJ732AB, expiry date: 30-Jun-2022, strength: not reported) via unknown route in unknown administration site for immunisation.  On 17-Oct-2021, the patient developed a non-serious total time out of range is 2 days with a minimum of 9.2c and maximum of 28.3c; 30 minutes with a minimum of 12.3c and maximum of 15.6c; 1 hour with a minimum of negative 1.8c and maximum of 1.8c reported with no adverse event (product temperature excursion issue) (unknown latency) following the administration of influenza quadrival A-B high dose hv vaccine.  Action taken: not applicable.  Outcome: Unknown.
Child's right upper arm red, swollen and warm to touch. Doctor recommended ice, Benadryl, and Tylenol.
Twenty days after receiving the fifth dose of the COVID vaccine (Moderna Bivalent) I started to experience symptoms of a sore throat. I decided to test myself the next morning for COVID-19 and the test came back positive. I called my doctor's office and I was prescribed Paxlovid. I don't feel like it has really helped me very much. As of today, I feel pretty good, but I am still experiencing a little congestion, fatigue and my voice is still scratchy. I went to my doctor's office this past week and he did some blood work and noticed that my B-12 was low.
Rebound covid. tested positive on 5/15/2022 after testing negative 3 times since completing the treatment; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Rebound covid. tested positive on 5/15/2022 after testing negative 3 times since completing the treatment) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032r21A) for COVID-19 vaccination.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19.    No Medical History information was reported.   On 19-Nov-2021 at 3:00 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-May-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) at an unspecified dose. On 15-May-2022, the patient experienced COVID-19 (Rebound covid. tested positive on 5/15/2022 after testing negative 3 times since completing the treatment). At the time of the report, COVID-19 (Rebound covid. tested positive on 5/15/2022 after testing negative 3 times since completing the treatment) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-May-2022, SARS-CoV-2 test: positive (Positive) Positive. tested positive on 5/15/2022 after testing negative 3 times since completing the treatment.         No concomitant medication was reported. The patient was not taking any other medications/products within 2 weeks of starting COVID-19 treatment. The patient previously received a COVID-19 Vaccine. No treatment medication was reported. Company comment: This spontaneous case concerns a patient of an unknown age and gender, with no medical history reported, who experienced the non-serious unexpected AESI of COVID-19 (reported as Rebound covid) approximately 6 months after the third dose of mRNA-1273 vaccine. No details of previous doses were provided. As per narrative of the source document, he received Paxlovid (ritonavir) as COVID-19 treatment, and 10 days later he tested positive after testing negative 3 times since completing the treatment. No further clinical information was provided for medical reviewing. The benefit-risk relationship of the mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a patient of an unknown age and gender, with no medical history reported, who experienced the non-serious unexpected AESI of COVID-19 (reported as Rebound covid) approximately 6 months after the third dose of mRNA-1273 vaccine. No details of previous doses were provided. As per narrative of the source document, he received Paxlovid (ritonavir) as COVID-19 treatment, and 10 days later he tested positive after testing negative 3 times since completing the treatment. No further clinical information was provided for medical reviewing. The benefit-risk relationship of the mRNA-1273 is not affected by this report.
p/vax pt devel a fever of 101 r;pt hosp in ICU ro r/o sepsis;lab work (cultures) were negative;MD did not know if baby was over wrapped or had sepsis;pt recovered;